CA-SYSDIG
13.1.2022 17:56:06 CET | Business Wire | Press release
Sysdig, Inc., the unified container and cloud security leader, today announced that Gerald Combs, the Wireshark creator and project leader, has joined the company. Wireshark, an open source tool, is the world’s foremost and widely-used traffic protocol analyzer with more than 60 million downloads in the last 5 years, an average of one million per month. Loris Degioanni, CTO and Founder of Sysdig, partnered with Gerald to launch Wireshark more than 15 years ago. Gerald joins Sysdig’s open source team, which is a significant contributor to many open source projects, including Falco, eBPF, Sysdig open source, Sysdig Inspect, and other tools and libraries. With Gerald joining, Sysdig assumes responsibility for sponsoring and managing the Wireshark community and extending Wireshark’s use cases to the cloud ecosystem.
Wireshark is an open source GUI network package capturing tool that enables teams to monitor network traffic, learn protocols and packet basics, and troubleshoot network problems. For network admins, Wireshark is the de facto standard for checking health and security at a microscopic level. Wireshark takes packet captures and saves them for later viewing. Teams can filter through that traffic to find evidence from an incident. With more than 1,900 contributors, the number of integrations continues to expand. Adoption is broad as Wireshark can be used consistently across nearly any environment, including Windows, Linux, and macOS, among others.
“It’s amazing to see the lasting heritage of Wireshark, led by Gerald. You can guarantee most of the Fortune 2000 are actively using Wireshark,” said Loris Degioanni, CTO and Founder, Sysdig. “I am excited to be reunited with Gerald and to advance the project in the same way Sysdig supports Falco and the Sysdig open source project. This move ensures Wireshark will continue to innovate. Our goal at Sysdig is to empower Wireshark.”
The Importance of Healthy Open Source Projects
The Log4j and OpenSSL vulnerabilities have shown that large and small organizations rely on open source projects and major issues arise when critical vulnerabilities are found in these tools. Log4j spotlighted the importance of maintaining open source projects. Continuing to maintain the project’s health is of the utmost importance considering the widespread adoption of Wireshark.
The Wireshark Story
While studying network analyzers and creating a popular open source tool while working on his PhD in Italy, Loris was invited to the United States to do research on packets, which is where he met Gerald. Gerald joined Loris at CACE Technologies in the early 2000’s, where they collaborated and grew Wireshark. CACE Technologies was later acquired and since that time, Gerald has focused on growing the tool and ensuring Wireshark and its community have the resources needed to thrive.
“I am excited to be reunited with Loris and explore the opportunity we have to expand Wireshark to the cloud,” said Gerald Combs, Director of Open Source Projects, Sysdig. “My move to Sysdig and the subsequent move for Wireshark will give Wireshark the corporate sponsor it needs to continue moving forward. This is a significant milestone for Wireshark and with Sysdig’s backing, we will have the assistance we need to continue to evolve use cases for Wireshark.”
The Wireshark Future
Sysdig will ensure the community has the backing it needs, including supporting Gerald as the leader of the community, ensuring Wireshark has the resources needed to operate, and sponsoring SharkFest. Sysdig has an open source team that will contribute to Wireshark. Reunited, Gerald and Loris will investigate new innovative ways to address challenges with securing the cloud.
Sysdig’s Commitment to Open Source
Sysdig was founded as an open source company and the Sysdig platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source Sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the CNCF in 2018, is now an incubation-level hosted project with more than 40 million downloads.
Resources
- Read Loris’ blog: Sysdig Welcomes Gerald and the Wireshark Community .
- Read Gerald's blog: We Have a New Sponsor .
- Visit Wireshark.org .
- Visit Sysdig.com .
About Sysdig
Sysdig is driving the standard for securing the cloud, empowering organizations to confidently secure containers, Kubernetes, and cloud services. The Sysdig platform enables teams to secure the build, detect and respond to runtime threats, and continuously manage cloud configurations, permissions and compliance. Sysdig is a SaaS platform built on an open source stack that includes Falco and Sysdig open source, the open standards for runtime threat detection and response. The largest and most security conscious companies rely on Sysdig for container and cloud security. sysdig.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
